Registry of Febrile Neutropenia and Invasive Fungal Infections
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Objectives:
- To assess the percentage of febrile neutropenia and suspected fungal-related febrile episodes in patients receiving chemotherapy
- To explore the percentage/distribution of infectious origins of febrile neutropenia
- To explore the percentage/distribution of infectious pathogens of febrile neutropenia
- To explore clinical outcomes of different infectious origins/pathogens in febrile neutropenia episodes
- To have a clear view of therapeutic actions in the management of hematological patients with febrile neutropenia and suspected fungal-related febrile episodes
| Condition | Intervention |
|---|---|
|
Hematological Disease Febrile Neutropenia Fungal Infections |
Other: Patient registry |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | A Non-interventional Prospective Registry to Monitor the Events of Febrile Neutropenia and Invasive Fungal Infections and the Diagnostic and Therapeutic Management in Patients With Malignant Hematologic Diseases After Chemotherapy |
| Estimated Enrollment: | 100 |
| Study Start Date: | November 2011 |
| Estimated Study Completion Date: | August 2013 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Patient registry
Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
|
Other: Patient registry
Patient registry without study intervention
|
Detailed Description:
Objectives:
- To assess the percentage of febrile neutropenia and suspected fungal-related febrile episodes in patients receiving chemotherapy
- To explore the percentage/distribution of infectious origins of febrile neutropenia
- To explore the percentage/distribution of infectious pathogens of febrile neutropenia
- To explore clinical outcomes of different infectious origins/pathogens in febrile neutropenia episodes
- To have a clear view of therapeutic actions in the management of hematological patients with febrile neutropenia and suspected fungal-related febrile episodes
Study Design:
- This is a single institute, prospective, non-interventional registry for monitoring events of febrile neutropenia in hematological patients
- Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
Study Procedures: Data collection will include patients' basic information, underlying disease, baseline blood chemistry and blood cell counts, antifungal prophylaxis, C/T regimens, neutrophils and other blood cells, fever diagnosis and infectious sites work-up, clinical response, microbiology (including bacteria and fungus culture), renal and liver function, clinical diagnosis, work-up and intensive procedures and results, antifungal and antibacterial agents (including dosage, duration, and route), other drugs used (including antivirals, antineoplastics, corticosteroids, immunomodulators), clinical significant changes
Sample Size Calculation and Statistical Analysis: Approximately 100 febrile neutropenia episodes in 500 chemotherapy cycles will be collected. This is an observational and exploratory study without hypothesis tests. Study subjects will be collected and monitored under normal clinical practice, and the sample size will be limited due to the hospital scale and disease characteristic (the sample size calculation is inapplicable here). All evaluations will be shown by exploratory and descriptive data analysis. The number of cases for each investigative definition, the corresponding percentage and the 95% confidence interval will be described.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with newly diagnosed malignant hematological diseases
Inclusion Criteria:
- Patients with new diagnosed hematological diseases (acute and chronic myeloid and lymphoid leukemia, multiple myeloma, non-Hodgkin's and Hodgkin's lymphoma, myelodysplastic syndromes)
- Patients who are receiving chemotherapy and have ongoing febrile episodes
Exclusion Criteria:
- None
Contacts and Locations| Contact: Ming-Chung Wang, M.D. | +886-7-7317123 ext 3266 | wang9595@ms32.hinet.net |
| Taiwan | |
| Kaohsiung Chang Gung Memorial Hospital | Recruiting |
| Kaohsiung, Taiwan, 833 | |
| Contact: Ming-Chung Wang, M.D. +886-7-7317123 ext 3266 wang9595@ms32.hinet.net | |
| Principal Investigator: Ming-Chung Wang, M.D. | |
| Principal Investigator: | Ming-Chung Wang, M.D. | Kaohsiung Chang Gung Memorial Hospital |
More Information
No publications provided
| Responsible Party: | Chang Gung Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT01684189 History of Changes |
| Other Study ID Numbers: | MISP38887 |
| Study First Received: | September 10, 2012 |
| Last Updated: | September 11, 2012 |
| Health Authority: | Taiwan : Food and Drug Administration |
Additional relevant MeSH terms:
|
Fever Hematologic Diseases Mycoses Neutropenia Body Temperature Changes |
Signs and Symptoms Agranulocytosis Leukopenia Leukocyte Disorders |
ClinicalTrials.gov processed this record on May 19, 2013